

(a) (3) Exhibits

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
2.1	LLC Interest Purchase Agreement by and among Albany Molecular Research, Inc. and Brian W. Mulhall and Alan Weiss as the members of Whitehouse Analytical Laboratories, LLC, dated December 15, 2015 (incorporated herein by reference to Exhibit 2.1 to the Company's Annual Report on Form 10-K for the year ended December 15, 2015, filed with the Securities and Exchange Commission on March 30, 2016, File No. 001-35622).
2.2	Share Purchase Agreement by and among Albany Molecular Research, Inc., Gadea Grupo Farmaceutico, S.L., Exirisk Spain, S.L. and certain other persons thereto, dated as of July 16, 2015 (incorporated herein by reference to Exhibit 2.1 to the Company's 8-K filed with the Securities and Exchange Commission on July 16, 2015, File No. 001-35622).
2.3	Purchase Agreement by and between Aptuit, LLC and Albany Molecular Luxembourg S.à.r.l., dated as of January 8, 2015 (incorporated herein by reference to Exhibit 2.2 to the Company's 8-K filed with the Securities and Exchange Commission on January 15, 2015, File No. 001-35622).
2.4	Asset Purchase Agreement by and among Aptuit (West Lafayette), LLC, Aptuit, LLC, AMRI Americium, LLC, and Albany Molecular Research, Inc. dated as of January 8, 2015 (incorporated herein by reference to Exhibit 2.1 to the Company's 8-K filed with the Securities and Exchange Commission on January 15, 2015, File No. 001-35622).
2.5	Membership Interest Purchase Agreement by and among Oso Biopharm Holdings, LLC, Oso Biopharmaceuticals Manufacturing, LLC, ALO Acquisition LLC, and Albany Molecular Research, Inc. dated as of June 1, 2014 (incorporated herein by reference to Exhibit 2.1 to the Company's 8-K filed with the Securities and Exchange Commission on June 2, 2014, File No. 001-35622).
2.6	Agreement and Plan of Merger by and among Albany Molecular Research, Inc., AICu Acquisition Corp., Cedarburg Pharmaceuticals, Inc. and James Gale, dated March 22, 2014 (incorporated herein by reference to Exhibit 2.1 to the Company's 8-K filed with the Securities and Exchange Commission on March 24, 2014, File No. 001-35622).
2.7	Share Purchase Agreement by and between Albany Molecular Research, Inc. and Lauro Cinquantasette S.p.A., dated as of May 5, 2016 (incorporated herein by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 6, 2016, File No. 001-35622).
2.8	Amendment letter by and among Albany Molecular Research, Inc., Albany Molecular Research Luxembourg Sarl, Evergreen S.r.l. and Lauro Cinquantasette S.p.A dated July 7, 2016, to the Share Purchase Agreement dated May 5, 2016 by and between Albany Molecular Research, Inc. and Lauro Cinquantasette S.p.A. (incorporated herein by reference to Exhibit 2.1 to the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2016, filed with the Securities and Exchange Commission on November 9, 2016, File No. 001-35622).
2.9	Amendment letter by and among Albany Molecular Research, Inc., Albany Molecular Research Luxembourg Sarl, Evergreen S.r.l. and Lauro Cinquantasette S.p.A dated August 8, 2016, to the Share Purchase Agreement dated May 5, 2016 by and between Albany Molecular Research, Inc. and Lauro Cinquantasette S.p.A. (incorporated herein by reference to Exhibit 2.2 to the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2016, filed with the Securities and Exchange Commission on November 9, 2016, File No. 001-35622).